Hormonal
Multi-targeting agonists (tirzepatide and peptide 20) that activate GIPR, GLP-1R, and GCGR provide superior metabolic efficacy compared to GLP-1 mono-agonists (like semaglutide) by leveraging distinct structural binding modes and retaining glucagon receptor function.
For individuals managing Type 2 Diabetes or Obesity, newer multi-targeting therapies (like tirzepatide) that activate multiple metabolic receptors (GIP, GLP-1, and Glucagon) have demonstrated superior weight loss and glucose control compared to older GLP-1-only medications. This suggests that targeting multiple hormonal pathways simultaneously may offer better clinical outcomes than single-pathway treatments.
Tirzepatide is an investigational once-weekly GIPR/GLP-1R dual agonist with a profound therapeutic superiority in reducing blood glucose and body weight beyond several approved drugs such as semaglutide and dulaglutide... Retention of glucagon function is required to achieve such an advantage over GLP-1 mono-therapy.
Why this rating
The paper combines high-resolution cryo-EM structural data with referenced clinical trial outcomes, providing strong mechanistic and efficacy evidence.
Source
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
Fenghui Zhao et al. · Nature Communications · 2022
DOI 10.1038/s41467-022-28683-0
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →